EBV lytic infection enhances transformation of B-lymphocytes infected with EBV in the presence of T-lymphocytes

Journal of Medical Virology

Volumn 84, Issue 3, 2012, Pages 504-510

  Katsumura, Koichi Ricardo ^a,b   Maruo, Seiji ^a   Takada, Kenzo ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b University of Wisconsin Health   (United States)

Author keywords

BZLF1; Epstein Barr virus; IL 13; Lymphoproliferation; Lytic infection

Indexed keywords

IMMEDIATE EARLY PROTEIN BZLF1; INTERLEUKIN 13;

ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE TRANSFORMATION; NONHUMAN; PARACRINE SIGNALING; PROTEIN EXPRESSION; T LYMPHOCYTE;

B-LYMPHOCYTES; CELL LINE; CELL TRANSFORMATION, VIRAL; HERPESVIRUS 4, HUMAN; HUMANS; INTERLEUKIN-13; PARACRINE COMMUNICATION; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; TRANS-ACTIVATORS; VIRAL MATRIX PROTEINS;

HUMAN HERPESVIRUS 4;

EID: 84855891334     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23208     Document Type: Article

References (43)

1. Ahsan N, Kanda T, Nagashima K, Takada K. 2005. Epstein-Barr virus transforming protein LMP1 plays a critical role in virus production. J Virol 79: 4415-4424.
2. Chang YN, Dong DL, Hayward GS, Hayward SD. 1990. The Epstein-Barr virus Zta transactivator: A member of the bZIP family with unique DNA-binding specificity and a dimerization domain that lacks the characteristic heptad leucine zipper motif. J Virol 64: 3358-3369.
3. Chatterjee M, Osborne J, Bestetti G, Chang Y, Moore PS. 2002. Viral IL-6 induced cell proliferation and immune evasion of interferon activity. Science 298: 1432-1435.
4. Chiang AKS, Tao Q, Srivastava G, Faith CSH. 1996. Nasal NK- and T-cell lymphomas share the same type of Epstein-Barr virus latency as nasopharyngeal carcinoma and Hodgkin's disease. Int J Cancer 68: 285-290.
5. Condit RC. 2001. In: Principles of virology. Knipe DM, Howley PM, Griffin DE, et al. editors. Fields virology. 4th edition. Philadelphia: Lippincott Williams and Wilkins, pp 19-51.
6. Countryman J, Miller G. 1985. Activation of expression of latent Epstein-Barr herpesvirus after gene transfer with a small cloned subfragment of heterogenous viral DNA. PNAS 82: 4085-4089.
7. Drouet E, Brousset P, Fares F, Icart J, Verniol C, Meggetto F, Schlaifer D, Desmorat-Coat H, Rigal-Huguet F, Niveleau A, Delsol G. 1999. High Epstein-Barr virus serum load and elevated titers of anti-ZEBRA antibodies in patients with EBV-harboring tumor cells of Hodgkin's disease. J Med Virol 57: 383-389.
8. Eliopoulos AG, Gallagher NJ, Blake SMS, Dawson CW, Young LS. 1999. Activation of the p38 mitogen-activated protein kinase pathway by Epstein- Barr virus-encoded latent membrane protein 1 coregulates interleukin-6 and interleukin-8 production. J Biol Chem 274: 16085-106096.
9. Farrell PJ, Rowe DT, Rooney CM, Kouzarides T. 1989. Epstein-Barr virus BZLF1 trans-activator specifically binds to a consensus AP-1 site and is related to c-fos. EMBO J 8: 127-132.
10. Feederle R, Kost M, Baumann M, Janz A, Drouet E, Hammerschmidt W, Delecluse HJ. 2000. The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators. EMBO J 19: 3080-3089.
11. Flemington EK, Borras AM, Lytle JP, Speck SH. 1992. Characterization of the Epstein-Barr virus BZLF1 protein transactivation domain. J Virol 66: 922-929.
12. + T cell reactivity. J Virol 79: 5477-5488.
13. Hershey GKK. 2003. IL-13 receptors and signaling pathways: An evolving web. J Allergy Clin Immunol 111: 677-690.
14. Hong GK, Gulley ML, Feng WH, Delecluse HJ, Holley-Guthrie E, Kenney SC. 2005. Epstein-Barr virus lytic infection contributes to lymphoproliferative disease in a SCID mouse model. J Virol 79: 13993-14003.
15. Hoshikawa Y, Satoh Y, Murakami M, Maeta M, Kaibara N, Ito H, Kurata T, Sairenji T. 2002. Evidence of lytic infection of Epstein-Barr virus (EBV) in EBV-positive gastric carcinoma. J Med Virol 66: 351-359.
16. Hsu DH, de Waal Malefyt R, Fiorentino DF, Dang MN, Vieira P, de Vries J, Spits H, Mosmann TR, Moore KW. 1990. Expression of interleukin-10 activity by Epstein-Barr virus protein BCRF1. Science 250: 830-832.
17. Imai S, Nishikawa J, Takada K. 1998. Cell-to-cell contact as an efficient mode of Epstein-Barr virus infection of diverse human epithelial cells. J Virol 72: 4371-4378.
18. Jones RJ, Seaman WT, Feng WH, Barlow E, Dickerson S, Dlecluse HJ, Kenney SC. 2007. Roles of lytic viral infection and IL-6 in early versus late passage lymphoblastoid cell lines and EBV-associated lymphoproliferative disease. Int J Cancer 121: 1274-1281.
19. Kapp U, Yeh WC, Patterson B, Elia AJ, Kagi D, Ho A, Hessel A, Tipsword M, Williams A, Mirtsos C, Itie A, Moyle M, Mak TW. 1999. Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells. J Exp Med 189: 1939-1945.
20. Katsumura KR, Maruo S, Wu Y, Kanda T, Takada K. 2009. Quantitative evaluation of the role of Epstein-Barr virus immediate-early protein BZLF1 in B-cell transformation. J Gen Virol 90: 2331-2341.
21. Kieff E, Rickinson AB. 2007. In: Epstein-Barr virus and its replication. Knipe DM, Howley PM, editors. Fields virology. 5th edition. Philadelphia: Lippincott Williams and Wilkins, pp 2603-2654.
22. Lindow M, Nansen A, Bartholdy C, Stryhn A, Hansen NJV, Boesen TP, Wells TNC, Schwartz TW, Thomsen AR. 2003. The virus-encoded chemokine vMIP-II inhibits virus-induced Tc1-driven inflammation. J Virol 77: 7393-7400.
23. Liu MY, Shih YY, Li LY, Chou SP, Sheen TS, Chen CL, Yang CS, Chen JY. 2000. Expression of the Epstein-Barr virus BHRF1 gene, a homologue of Bcl-2, in nasopharyngeal carcinoma tissue. J Med Virol 61: 241-250.
24. Mahot S, Sergeant A, Drouet E, Gruffat H. 2003. A novel function for the Epstein-Barr virus transcription factor EB1/Zta: Induction of transcription of the hIL-10 gene. J Gen Virol 84: 965-974.
25. Maruo S, Yang L, Takada K. 2001. Roles of Epstein-Barr virus glycoproteins gp350 and gp25 in the infection of human epithelial cells. J Gen Virol 82: 2373-2383.
26. Montaner S, Sodhi A, Molinolo A, Bugge TH, Sawai ET, He Y, Li Y, Ray PE, Gutkind JS. 2003. Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi's sarcoma and can promote the tumorigenic potential of viral latent genes. Cancer cell 3: 23-36.
27. Moore PS, Boshoff C, Weiss RA, Chang Y. 1996. Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. Science 274: 1739-1744.
28. Moss DJ, Rickinson AB, Pope JH. 1978. Long-term T-cell-mediated immunity to Epstein-Barr virus in man. I. Complete regression of virus-induced transformation in cultures of seropositive donor leukocytes. Int J Cancer 22: 662-668.
29. Oudejans JJ, Jiwa M, van der Brule AJ, Grasser FA, Horstman A, Vos W, Kluin PM, van der Val P, Walboomers JM, Meijer CJ. 1995. Detection of heterogeneous Epstein-Barr virus gene expression patterns within individual post-transplantation lymphoproliferative disorders. Am J Pathol 147: 923-933.
30. Pallesen G, Sandvej K, Hamilton-Dutoit SJ, Rowe M, Young LS. 1991. Activation of Epstein-Barr virus replication in Hodgkin and Reed-Sternberg cells. Blood 78: 1162-1165.
31. Rickinson AB, Kieff E. 2007. In: Epstein-Barr virus. Knipe DM, Howley PM, editors. Fields virology. 5th edition. Philadelphia: Lippincott Williams and Wilkins. pp 2655-2700.
32. Shimizu N, Tanabe-Tochikura A, Kuroiwa Y, Takada K. 1994. Isolation of Epstein-Barr virus (EBV)-negative cell clones from the EBV-positive Burkitt's lymphoma (BL) line Akata: Malignant phenotypes of BL cells are dependent on EBV. J Virol 68: 6069-6073.
33. Stuart AD, Stewart JP, Arrand JR, Mackett N. 1995. The Epstein-Barr virus encoded cytokine viral interleukin-10 enhances transformation of human B lymphocytes. Oncogene 11: 1711-1719.
34. Swaminathan S, Hesselton R, Sullivan J, Kieff E. 1993. Epstein-Barr virus recombinants with specifically mutated BCRF1 gene. J Virol 67: 7406-7413.
35. Takada K, Shimizu N, Sakuma S, Ono Y. 1986. trans activation of the latent Epstein-Barr virus (EBV) genome after transfection of the EBV DNA fragment. J Virol 57: 1016-1022.
36. Terabe M, Matsui S, Noben-Trauth N, Chen H, Watson C, Donaldson DD, Carbone DP, Paul WE, Berzofsky JA. 2000. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol 1: 515-520.
37. Tsai SC, Lin SJ, Chen PW, Luo WY, Yeh TH, Wang HW, Chen CJ, Tsai CH. 2009. EBV Zta protein induces the expression of interleukin-13, promoting the proliferation of EBV-infected B cells and lymphoblastoid cell lines. Blood 114: 109-118.
38. Waldele K, Schneider G, Ruckes T, Grassmann R. 2004. Interleukin-13 overexpression by Tax transactivation: A potential autocrine stimulus in human T-cell leukemia virus-infected lymphocytes. J Virol 78: 6081-6090.
39. Wen W, Iwakiri D, Yamamoto K, Maruo S, Kanda T, Takada K. 2007. Epstein-Barr virus BZLF1 gene, a switch from latency to lytic infection, is expressed as an immediate-early gene after primary infection of B-lymphocytes. J Virol 81: 1037-1042.
40. Xue SA, Labrecque LG, Lu QL, Ong SK, Lampert IA, Kazembe P, Molyneux E, Broadhead RL, Borgstein E, Griffin BE. 2002. Promiscuous expression of Epstein-Barr virus genes in Burkitt's lymphoma from the central African country Malawi. Int J Cancer 99: 635-643.
41. Yajima M, Imadome K, Nakagawa A, Watanabe S, Terashima K, Nakamura H, Ito M, Shimizu N, Honda M, Yamamoto M, Fujiwara S. 2008. A new humanized mouse model of Epstein-Barr virus infection that reproduces persistent infection, lymphoproliferative disorder, and cell-mediated and humoral immune responses. J Infect Dis 198: 673-682.
42. Schulz TF. 2006. The pleiotropic effects of Kaposi's sarcoma herpesvirus. J Pathol 208: 197-198.
43. Yu CR, Kirken RA, Malabarba MG, Young HA, Ortaldo JR. 1998. Differential regulation of the Janus kinase-STAT pathway and biologic function of IL-13 in primary human NK and T cells: A comparative study with IL-4. J Immunol 161: 218-227.